Tle1 tumor suppressor negatively regulates inflammation in vivo and modulates NF-κB inflammatory pathway

Selvi Ramasamy, Borja Saez, Subhankar Mukhopadhyay, Daching Ding, Alwiya M. Ahmed, Xi Chen, Ferdinando Pucci, Rae'e Yamin, Jianfeng Wang, Mikael J. Pittet, Cassandra M. Kelleher, David T. Scadden, David A. Sweetser

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Tle1 (transducin-like enhancer of split 1) is a corepressor that interacts with a variety of DNA-binding transcription factors and has been implicated in many cellular functions; however, physiological studies are limited. Tle1-deficient (Tle1Δ/Δ) mice, although grossly normal at birth, exhibit skin defects, lung hypoplasia, severe runting, poor body condition, and early mortality. Tle1Δ/Δ mice display a chronic inflammatory phenotype with increased expression of inflammatory cytokines and chemokines in the skin, lung, and intestine and increased circulatory IL-6 and G-CSF, along with a hematopoietic shift toward granulocyte macrophage progenitor and myeloid cells. Tle1Δ/Δ macrophages produce increased inflammatory cytokines in response to Toll-like receptor (TLR) agonists and lipopolysaccharides (LPS), and Tle1Δ/Δ mice display an enhanced inflammatory response to ear skin 12-O-tetradecanoylphorbol-13-acetate treatment. Loss of Tle1 not only results in increased phosphorylation and activation of proinflammatory NF-κB but also results in decreased Hes1 (hairy and enhancer of split-1), a negative regulator of inflammation in macrophages. Furthermore, Tle1Δ/Δ mice exhibit accelerated growth of B6-F10 melanoma xenografts. Our work provides the first in vivo evidence, to our knowledge, that TLE1 is a major counterregulator of inflammation with potential roles in a variety of inflammatory diseases and in cancer progression.

Original languageEnglish (US)
Pages (from-to)1871-1876
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume113
Issue number7
DOIs
StatePublished - Feb 16 2016
Externally publishedYes

Fingerprint

Transducin
Inflammation
Neoplasms
Skin
Macrophages
Cytokines
Co-Repressor Proteins
Lung
Granulocyte-Macrophage Progenitor Cells
Toll-Like Receptors
Tetradecanoylphorbol Acetate
Granulocyte Colony-Stimulating Factor
Myeloid Cells
Chemokines
Heterografts
Intestines
Ear
Lipopolysaccharides
Melanoma
Interleukin-6

Keywords

  • HES1
  • Inflammation
  • NF-κB
  • TLE1
  • Tumor suppressor

ASJC Scopus subject areas

  • General

Cite this

Tle1 tumor suppressor negatively regulates inflammation in vivo and modulates NF-κB inflammatory pathway. / Ramasamy, Selvi; Saez, Borja; Mukhopadhyay, Subhankar; Ding, Daching; Ahmed, Alwiya M.; Chen, Xi; Pucci, Ferdinando; Yamin, Rae'e; Wang, Jianfeng; Pittet, Mikael J.; Kelleher, Cassandra M.; Scadden, David T.; Sweetser, David A.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 113, No. 7, 16.02.2016, p. 1871-1876.

Research output: Contribution to journalArticle

Ramasamy, S, Saez, B, Mukhopadhyay, S, Ding, D, Ahmed, AM, Chen, X, Pucci, F, Yamin, R, Wang, J, Pittet, MJ, Kelleher, CM, Scadden, DT & Sweetser, DA 2016, 'Tle1 tumor suppressor negatively regulates inflammation in vivo and modulates NF-κB inflammatory pathway', Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 7, pp. 1871-1876. https://doi.org/10.1073/pnas.1511380113
Ramasamy, Selvi ; Saez, Borja ; Mukhopadhyay, Subhankar ; Ding, Daching ; Ahmed, Alwiya M. ; Chen, Xi ; Pucci, Ferdinando ; Yamin, Rae'e ; Wang, Jianfeng ; Pittet, Mikael J. ; Kelleher, Cassandra M. ; Scadden, David T. ; Sweetser, David A. / Tle1 tumor suppressor negatively regulates inflammation in vivo and modulates NF-κB inflammatory pathway. In: Proceedings of the National Academy of Sciences of the United States of America. 2016 ; Vol. 113, No. 7. pp. 1871-1876.
@article{c4e435206a4949c29412f242d57f1956,
title = "Tle1 tumor suppressor negatively regulates inflammation in vivo and modulates NF-κB inflammatory pathway",
abstract = "Tle1 (transducin-like enhancer of split 1) is a corepressor that interacts with a variety of DNA-binding transcription factors and has been implicated in many cellular functions; however, physiological studies are limited. Tle1-deficient (Tle1Δ/Δ) mice, although grossly normal at birth, exhibit skin defects, lung hypoplasia, severe runting, poor body condition, and early mortality. Tle1Δ/Δ mice display a chronic inflammatory phenotype with increased expression of inflammatory cytokines and chemokines in the skin, lung, and intestine and increased circulatory IL-6 and G-CSF, along with a hematopoietic shift toward granulocyte macrophage progenitor and myeloid cells. Tle1Δ/Δ macrophages produce increased inflammatory cytokines in response to Toll-like receptor (TLR) agonists and lipopolysaccharides (LPS), and Tle1Δ/Δ mice display an enhanced inflammatory response to ear skin 12-O-tetradecanoylphorbol-13-acetate treatment. Loss of Tle1 not only results in increased phosphorylation and activation of proinflammatory NF-κB but also results in decreased Hes1 (hairy and enhancer of split-1), a negative regulator of inflammation in macrophages. Furthermore, Tle1Δ/Δ mice exhibit accelerated growth of B6-F10 melanoma xenografts. Our work provides the first in vivo evidence, to our knowledge, that TLE1 is a major counterregulator of inflammation with potential roles in a variety of inflammatory diseases and in cancer progression.",
keywords = "HES1, Inflammation, NF-κB, TLE1, Tumor suppressor",
author = "Selvi Ramasamy and Borja Saez and Subhankar Mukhopadhyay and Daching Ding and Ahmed, {Alwiya M.} and Xi Chen and Ferdinando Pucci and Rae'e Yamin and Jianfeng Wang and Pittet, {Mikael J.} and Kelleher, {Cassandra M.} and Scadden, {David T.} and Sweetser, {David A.}",
year = "2016",
month = "2",
day = "16",
doi = "10.1073/pnas.1511380113",
language = "English (US)",
volume = "113",
pages = "1871--1876",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "7",

}

TY - JOUR

T1 - Tle1 tumor suppressor negatively regulates inflammation in vivo and modulates NF-κB inflammatory pathway

AU - Ramasamy, Selvi

AU - Saez, Borja

AU - Mukhopadhyay, Subhankar

AU - Ding, Daching

AU - Ahmed, Alwiya M.

AU - Chen, Xi

AU - Pucci, Ferdinando

AU - Yamin, Rae'e

AU - Wang, Jianfeng

AU - Pittet, Mikael J.

AU - Kelleher, Cassandra M.

AU - Scadden, David T.

AU - Sweetser, David A.

PY - 2016/2/16

Y1 - 2016/2/16

N2 - Tle1 (transducin-like enhancer of split 1) is a corepressor that interacts with a variety of DNA-binding transcription factors and has been implicated in many cellular functions; however, physiological studies are limited. Tle1-deficient (Tle1Δ/Δ) mice, although grossly normal at birth, exhibit skin defects, lung hypoplasia, severe runting, poor body condition, and early mortality. Tle1Δ/Δ mice display a chronic inflammatory phenotype with increased expression of inflammatory cytokines and chemokines in the skin, lung, and intestine and increased circulatory IL-6 and G-CSF, along with a hematopoietic shift toward granulocyte macrophage progenitor and myeloid cells. Tle1Δ/Δ macrophages produce increased inflammatory cytokines in response to Toll-like receptor (TLR) agonists and lipopolysaccharides (LPS), and Tle1Δ/Δ mice display an enhanced inflammatory response to ear skin 12-O-tetradecanoylphorbol-13-acetate treatment. Loss of Tle1 not only results in increased phosphorylation and activation of proinflammatory NF-κB but also results in decreased Hes1 (hairy and enhancer of split-1), a negative regulator of inflammation in macrophages. Furthermore, Tle1Δ/Δ mice exhibit accelerated growth of B6-F10 melanoma xenografts. Our work provides the first in vivo evidence, to our knowledge, that TLE1 is a major counterregulator of inflammation with potential roles in a variety of inflammatory diseases and in cancer progression.

AB - Tle1 (transducin-like enhancer of split 1) is a corepressor that interacts with a variety of DNA-binding transcription factors and has been implicated in many cellular functions; however, physiological studies are limited. Tle1-deficient (Tle1Δ/Δ) mice, although grossly normal at birth, exhibit skin defects, lung hypoplasia, severe runting, poor body condition, and early mortality. Tle1Δ/Δ mice display a chronic inflammatory phenotype with increased expression of inflammatory cytokines and chemokines in the skin, lung, and intestine and increased circulatory IL-6 and G-CSF, along with a hematopoietic shift toward granulocyte macrophage progenitor and myeloid cells. Tle1Δ/Δ macrophages produce increased inflammatory cytokines in response to Toll-like receptor (TLR) agonists and lipopolysaccharides (LPS), and Tle1Δ/Δ mice display an enhanced inflammatory response to ear skin 12-O-tetradecanoylphorbol-13-acetate treatment. Loss of Tle1 not only results in increased phosphorylation and activation of proinflammatory NF-κB but also results in decreased Hes1 (hairy and enhancer of split-1), a negative regulator of inflammation in macrophages. Furthermore, Tle1Δ/Δ mice exhibit accelerated growth of B6-F10 melanoma xenografts. Our work provides the first in vivo evidence, to our knowledge, that TLE1 is a major counterregulator of inflammation with potential roles in a variety of inflammatory diseases and in cancer progression.

KW - HES1

KW - Inflammation

KW - NF-κB

KW - TLE1

KW - Tumor suppressor

UR - http://www.scopus.com/inward/record.url?scp=84959036636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959036636&partnerID=8YFLogxK

U2 - 10.1073/pnas.1511380113

DO - 10.1073/pnas.1511380113

M3 - Article

VL - 113

SP - 1871

EP - 1876

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 7

ER -